CLINICAL_TRIALS
trial_result
· 2019-06-11
Clinical Trial Update: A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]
Summary
Phase 2 trial update for LY2181308 Sodium in relapsed or refractory acute myeloid leukemia has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2019-06-11